Thousands of men with advanced prostate cancer could be denied a new drug after a U-turn by the NHS rationing body.
Enzalutamide extends life by at least five months in men who have run out of treatment options – with some patients surviving more than 18 months.
Help employers find you! Check out all the jobs and post your resume.
